Editas Medicine grants CMO 950K stock options

Editas Medicine granted its Chief Medical Officer stock options for 950,000 shares at a $3.03 exercise price, vesting over four years.

Rhea-AI Filing Summary

Editas Medicine, Inc. (EDIT) reported that EVP and Chief Medical Officer Daniel Scott Ory received a grant of stock options covering 950,000 shares of common stock on September 8, 2026. The options have an exercise price of $3.03 per share and are scheduled to vest over four years, with 25% vesting on October 15, 2027 and the remaining 75% vesting in equal monthly installments through October 15, 2030. Following this grant, he holds 950,000 stock options directly, which expire on September 7, 2036.

Insider Trade Summary

Grant/Award: 950,000 shares

Grant/Award 1 txn

Insider Ory Daniel Scott

Role EVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	950,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 950,000 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on September 8, 2026 and is scheduled to vest over four years, with 25% of the shares to vest on October 15, 2027 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 15, 2030.

Key Figures

Stock options granted: 950,000 options Underlying common shares: 950,000 shares Exercise price: $3.03 per share +4 more

7 metrics

Stock options granted 950,000 options Grant to EVP, Chief Medical Officer on September 8, 2026

Underlying common shares 950,000 shares Each option represents the right to buy one share of common stock

Exercise price $3.03 per share Exercise price for the granted stock options

Initial vesting date October 15, 2027 Date when 25% of the option shares are scheduled to vest

Final vesting date October 15, 2030 End of the vesting period for the remaining option shares

Expiration date September 7, 2036 Expiration of the granted stock options if not exercised earlier

Options held after transaction 950,000 options Total stock options reported as held directly after the grant

Key Terms

Stock Option, vest, exercise price, expiration date

4 terms

Stock Option financial

"This option was granted on September 8, 2026 and is scheduled to vest over four years"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vest financial

"is scheduled to vest over four years, with 25% of the shares to vest on October 15, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"The options have an exercise price of $3.03 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"which expire on September 7, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did EDIT report for Daniel Scott Ory?

Editas Medicine reported that Daniel Scott Ory received a grant of stock options for 950,000 shares of common stock on September 8, 2026, as part of his equity compensation.

What is the exercise price of the new stock options granted by EDIT?

The stock options granted to Daniel Scott Ory have an exercise price of $3.03 per share for the underlying Editas Medicine common stock.

How do the EDIT stock options granted to the Chief Medical Officer vest?

The options are scheduled to vest over four years: 25% of the shares vest on October 15, 2027, and the remaining 75% vest in equal monthly installments through October 15, 2030.

When do the newly granted EDIT stock options expire?

The stock options granted to Daniel Scott Ory are scheduled to expire on September 7, 2036, if not exercised earlier and subject to the terms of the grant.

How many Editas Medicine stock options does Daniel Scott Ory hold after this grant?

Following this grant, Daniel Scott Ory is reported to hold 950,000 stock options for Editas Medicine common stock as a direct holding.

Were the EDIT stock option grants made under a Rule 10b5-1 trading plan?

The filing indicates that the Rule 10b5-1 trading plan affirmation box was not checked, so these option grants are not reported as made under a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:58 PM Accepted by SEC EDGAR 09/09/2026 - 04:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ory Daniel Scott

(Last) (First) (Middle)

C/O EDITAS MEDICINE, INC.

11 HURLEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.03	09/08/2026		A		950,000		(1)	09/07/2036	Common Stock	950,000	$0	950,000	D

Explanation of Responses:

1. This option was granted on September 8, 2026 and is scheduled to vest over four years, with 25% of the shares to vest on October 15, 2027 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 15, 2030.

Remarks:

	/s/ Daniel Ory, M.D.	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)